Keros Therapeutics (NASDAQ:KROS) Director Sells $28,140.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Alpna Seth sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Down 4.4%

Shares of KROS stock traded down $0.47 during mid-day trading on Friday, hitting $10.30. 163,405 shares of the company’s stock were exchanged, compared to its average volume of 380,127. Keros Therapeutics, Inc. has a fifty-two week low of $9.79 and a fifty-two week high of $22.55. The stock has a 50-day simple moving average of $11.35 and a two-hundred day simple moving average of $15.20. The stock has a market cap of $203.86 million, a price-to-earnings ratio of -3.42 and a beta of 0.94.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $1.93 million. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -5.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in KROS. AQR Capital Management LLC purchased a new position in shares of Keros Therapeutics in the 1st quarter worth $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after purchasing an additional 2,982 shares during the period. Goldman Sachs Group Inc. raised its position in Keros Therapeutics by 38.3% in the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after purchasing an additional 205,022 shares during the period. Creative Planning raised its position in Keros Therapeutics by 40.2% in the second quarter. Creative Planning now owns 24,226 shares of the company’s stock valued at $323,000 after purchasing an additional 6,948 shares during the period. Finally, Rhumbline Advisers raised its position in Keros Therapeutics by 16.0% in the second quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after purchasing an additional 7,146 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Wells Fargo & Company decreased their price objective on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.